Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Earnings release covers Tarsus Pharmaceuticals’ three and six months ended June 30, 2026.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Earnings release covers Tarsus Pharmaceuticals’ three and six months ended June 30, 2026
- Exhibit 99.1 contains the company’s operating results and accompanying financial details
- Results were furnished under Item 2.02, signaling public disclosure without filing incorporation into registration statements
Item EX-99.1 · Exhibit EX-99.1
- Q2 XDEMVY sales $173.9M, up more than 69% year over year, validating strong commercial adoption
- Full-year 2026 XDEMVY sales guidance raised to $685–705M, signaling increased management confidence in demand
- Gross margin remained 93%, while SG&A reached $150.7M and quarterly net loss narrowed to $18.6M
- Cash, equivalents and marketable securities totaled $449.7M, supporting continued commercial investment and pipeline expansion
- Pending Alkeus acquisition adds Phase 3 Stargardt program, while $125M private placement strengthens funding but may dilute shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.